Loading...
XTAECBI
Market cap14mUSD
Dec 24, Last price  
34.00ILS
1D
-1.16%
1Q
-14.79%
Jan 2017
-85.86%
IPO
-96.67%
Name

Clal Biotechnology Industries Ltd

Chart & Performance

D1W1MN
XTAE:CBI chart
P/E
—
P/S
51,276.58
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.21%
Rev. gr., 5y
-61.79%
Revenues
104k
-71.89%
1,404,0002,062,0001,339,0003,182,0004,745,0003,545,0009,067,0007,671,0003,452,00023,899,00025,417,00024,183,00043,461,00012,767,000113,293,00074,544,00076,961,000370,000104,000
Net income
-31m
L-49.71%
-57,137,000-15,442,000-44,557,000-83,042,00065,425,000350,868,00087,333,000-93,554,000-151,602,000-367,635,000-118,462,000-213,820,000-27,893,000-44,942,000-154,112,000109,027,000-89,583,000-61,740,000-31,051,000
CFO
-9m
L-85.58%
-17,434,000-23,549,000-47,049,000-52,415,000-86,860,000-111,926,000-102,451,000-81,222,000-148,976,000-115,952,000-146,999,000-112,633,000-91,405,000-86,981,00027,029,000-33,226,000-41,327,000-59,037,000-8,513,000
Dividend
Mar 29, 202122.3722 ILS/sh

Profile

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel. It invests between $0.5 million and $10 million per company. It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies. Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel with an additional office in Cambridge, Massachusetts. It operates as a former subsidiary of Clal Industries and Investments Ltd.
URL
https://www.cbi.co.il/
IPO date
May 30, 2007
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
104
-71.89%
370
-99.52%
76,961
3.24%
Cost of revenue
5,484
31,321
119,331
Unusual Expense (Income)
NOPBT
(5,380)
(30,951)
(42,370)
NOPBT Margin
Operating Taxes
107,778
113,953
89
Tax Rate
NOPAT
(113,158)
(144,904)
(42,459)
Net income
(31,051)
-49.71%
(61,740)
-31.08%
(89,583)
-182.17%
Dividends
(36,000)
Dividend yield
19.22%
Proceeds from repurchase of equity
222
23,694
(8,636)
BB yield
-0.36%
-24.05%
4.61%
Debt
Debt current
5,441
1,850
2,433
Long-term debt
35,138
16,828
20,931
Deferred revenue
24,522
Other long-term liabilities
27,392
370
Net debt
(110,994)
(144,451)
(157,519)
Cash flow
Cash from operating activities
(8,513)
(59,037)
(41,327)
CAPEX
(5)
(1,273)
(1,593)
Cash from investing activities
7,655
(10,955)
79,180
Cash from financing activities
(1,180)
20,054
(51,540)
FCF
(104,781)
(140,064)
57,569
Balance
Cash
13,356
12,885
53,049
Long term investments
138,217
150,244
127,834
Excess cash
151,568
163,110
177,035
Stockholders' equity
(1,308,181)
(1,140,937)
(946,374)
Invested Capital
1,465,346
1,322,565
1,321,317
ROIC
ROCE
EV
Common stock shares outstanding
156,846
156,846
158,440
Price
0.40
-36.78%
0.63
-46.87%
1.18
-40.21%
Market cap
62,268
-36.78%
98,499
-47.40%
187,276
-41.25%
EV
(26,676)
(27,082)
195,532
EBITDA
(4,854)
(13,308)
(19,859)
EV/EBITDA
5.50
2.03
Interest
3,544
3,725
7,428
Interest/NOPBT